Recruiting first, then most recently updated. Showing 26 of 26.
- A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal InsufficiencyRecruitingNCT07262333Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune PneumoniaRecruitingNCT07388680Phase 2/3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Preliminary Human Trials of F230 TabletsRecruitingNCT06899815Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.Not yet recruitingNCT07412236Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Efficacy and Safety of Pirfenidone Capsules in the Treatment of PneumoconiosisRecruitingNCT05288179Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- F573 for Injection for the Treatment of Liver Injury/FailureRecruitingNCT05689645Phase 2
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver FibrosisRecruitingNCT05905172Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- The Phase Ⅰd Clinical Trial of Hydronidone CapsulesCompletedNCT07262346Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- [¹⁴C] Hydronidone Mass Balance StudyCompletedNCT07471217Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir AmibufenamideCompletedNCT07295873Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy ControlsCompletedNCT07394309Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver CirrhosisCompletedNCT07343778Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- QTc Assessment in a Single-Dose Study of Hydronidone CapsulesCompletedNCT07263152Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver FibrosisCompletedNCT07417553Phase 2
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver FibrosisCompletedNCT07364448Phase 2
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.CompletedNCT03902509Phase 2
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.CompletedNCT05115942Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- F573 Ia Clinical TrialCompletedNCT04820049Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and PharmacokineticsStatus unknownNCT04126538Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Study on PK of Hydronidone in Patients and Special PopulationCompletedNCT04123769Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Study on Pharmacokinetics of HydronidoneCompletedNCT04162821Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Study on Hydronidone Capsule BECompletedNCT04125056Not applicable
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese SubjectsCompletedNCT04124081Phase 1
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)Status unknownNCT03857854Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung DiseaseStatus unknownNCT03856853Phase 3
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group
- Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung InjuryStatus unknownNCT02296281Phase 2
Sponsor listed in the registry: Beijing Continent Pharmaceutical Co, Ltd. · Beijing Continent Pharmaceutical Co, Ltd. — acquired company within the GNI Group Ltd. group